According to Zhitong Finance App News, Bohui Innovation (300318.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 396 million yuan, a year-on-year decrease of 2.09%. The net loss attributable to shareholders of the listed company was RMB 15.6066 million, and the net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was RMB 148.19,900.
During the reporting period, the company's main products sold in vitro diagnostics were human trace element testing and HPV testing. The end users were hospitals and third-party testing institutions. Sales of the company's HPV products increased year-on-year during the reporting period, but with the full implementation of the collection results in Anhui, the sales price of the company's HPV products decreased significantly; testing volume of trace element products declined year-on-year due to fewer newborns and replacement of competitive products. As a result, the operating income of in vitro diagnostic products was basically the same as the same period last year.
During the reporting period, the main products of the company's non-medical testing business were compact mass spectrometry detectors (CMS). The main customers were research institutes engaged in the fields of medicine and health, biotechnology, chemical chemistry, food safety, etc., with revenue falling 36.95% year on year, mainly because after high growth last year, demand stabilized and declined year-on-year; second, some key materials were affected by disruptions in supplier production capacity, and production replacement was carried out after completion of supply quality verification, causing delays in delivery of some orders.